V1RB1 Inhibitors
V1RB1 inhibitors are a class of chemical agents that specifically target and inhibit the action of a receptor known as V1RB1. The V1RB1 receptor, also known as the vasopressin 1 receptor subtype B1, is a protein encoded by the human body that plays a significant role in physiological processes. It is a type of G protein-coupled receptor (GPCR), which is a large family of receptors that respond to a variety of external stimuli like light, hormones, and neurotransmitters. These receptors are characterized by their seven transmembrane domains, which allow them to transduce signals from outside the cell to the interior, initiating a cascade of intracellular events. V1RB1 inhibitors are designed to bind to this receptor, blocking its natural ligand, vasopressin, from activating it. By inhibiting the receptor's action, V1RB1 inhibitors modulate the signal transduction pathways that would normally be triggered by the receptor's activation.
Chemically, V1RB1 inhibitors can be diverse, encompassing a range of small molecules, peptides, or other synthetic compounds that have been engineered to interact with the receptor's active site or other critical regions essential for its activity. The interaction between the inhibitor and the receptor is highly specific, relying on the precise conformation of the receptor and the complementary structure of the inhibitor. This specificity is crucial to ensure that the inhibitor affects only the intended target without interfering with other GPCRs that have different physiological functions. The design of these inhibitors often involves a detailed understanding of the receptor's structure and the mechanisms by which it is activated and inactivated. Advanced techniques like X-ray crystallography, molecular modeling, and structure-activity relationship studies are typically employed to identify potential compounds and refine their properties for increased efficacy in blocking the receptor. While the inhibitors are varied, their common goal is the precise modulation of the receptor's activity through direct interaction, which affects the downstream signaling pathways and the physiological responses they control.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
NF 449 | 389142-38-5 | sc-203159 | 10 mg | $314.00 | 5 | |
NF449 is a potent and selective antagonist of the P2X1 receptor. V1RB1, being a G protein-coupled receptor (GPCR), could be indirectly inhibited by NF449, as P2X1 receptor activation can modulate GPCR signaling pathways through the regulation of intracellular calcium levels and the activation of various kinases. By blocking P2X1 receptor activation, NF449 would decrease calcium-mediated signaling and thereby diminish V1RB1-mediated responses. | ||||||
(S)-MCPG | 150145-89-4 | sc-202329 sc-202329A | 5 mg 25 mg | $146.00 $964.00 | ||
(S)-MCPG is a selective antagonist of the group I metabotropic glutamate receptors, specifically mGluR1 and mGluR5. V1RB1 signaling may be modulated by glutamate receptor activity, as glutamatergic signaling can influence a range of GPCR functions. Inhibition of mGluR1/5 by (S)-MCPG could lead to reduced excitatory neurotransmitter signaling, which could dampen V1RB1 activity if there is cross-talk between these receptor systems within the same neural circuits. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Losartan is an angiotensin II receptor type 1 (AT1) antagonist. Angiotensin II signaling can affect the function of other GPCRs, including V1RB1, through modulation of G-protein signaling cascades. Inhibition of AT1 by Losartan could prevent angiotensin II from exerting its effects on intracellular pathways that might otherwise enhance V1RB1 signaling, thereby indirectly inhibiting V1RB1 functional activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of the Rho-associated protein kinase (ROCK). ROCK modulates cytoskeletal dynamics and cell contraction, which can influence GPCR activity including V1RB1. Inhibiting ROCK may lead to a reduced GPCR-mediated cell response, including those mediated by V1RB1, by altering the cytoskeletal environment necessary for optimal receptor function and signaling. | ||||||
GW 9662 | 22978-25-2 | sc-202641 | 5 mg | $70.00 | 30 | |
GW9662 is an irreversible antagonist of peroxisome proliferator-activated receptor gamma (PPARγ). By inhibiting PPARγ, GW9662 may affect the expression of various proteins involved in GPCR signaling, potentially leading to altered V1RB1 signaling. PPARγ can regulate the transcription of genes involved in lipid metabolism and adipogenesis, which can indirectly influence the membrane environment and trafficking of GPCRs like V1RB1. | ||||||
Gabazine | 105538-73-6 | sc-211552 | 10 mg | $714.00 | 3 | |
Gabazine is a selective GABA-A receptor antagonist. By inhibiting GABAergic signaling, SR 95531 could lead to increased neuronal excitability. This heightened excitability might indirectly affect the activity of GPCRs such as V1RB1 by altering the baseline activity level of neurons that express both GABA-A receptors and V1RB1, potentially dampening V1RB1 signaling due to altered neurotransmitter release dynamics. | ||||||